Last reviewed · How we verify
NCT06707584: MRI
Role of MRI in Breast Cancer Subtypes
trial in MRI in Breast Cancer in 45 participants. Not yet recruiting.
10 August 2029
Quick facts
| Lead sponsor | Lamiaa Gomaa Ahmed Elsayed |
|---|---|
| Status | Not yet recruiting |
| Study type | OBSERVATIONAL |
| Enrollment | 45 |
| Start date | 1 April 2025 |
| Primary completion | 10 August 2029 |
| Estimated completion | 1 December 2030 |
Conditions studied
- MRI in Breast Cancer — all drugs for MRI in Breast Cancer →
Sponsor
Lamiaa Gomaa Ahmed Elsayed
Who can join
Eligibility, any sex, with MRI in Breast Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
efficacy of MRI in detection of breast cancer molecular subtypes instead of biopsy and immunohistochemistry
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06707584
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06707584 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Lamiaa Gomaa Ahmed Elsayed
- Last refreshed: 27 November 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06707584.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing